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Yes-associated protein (YAP) in pancreatic cancer: at the
epicenter of a targetable signaling network associated with
patient survival
Enrique Rozengurt1,2,3, James Sinnett-Smith1,2 and Guido Eibl 2,4
Pancreatic ductal adenocarcinoma (PDAC) is generally a fatal disease with no efficacious treatment modalities. Elucidation of
signaling mechanisms that will lead to the identification of novel targets for therapy and chemoprevention is urgently needed.
Here, we review the role of Yes-associated protein (YAP) and WW-domain-containing Transcriptional co-Activator with a PDZ-
binding motif (TAZ) in the development of PDAC. These oncogenic proteins are at the center of a signaling network that involves
multiple upstream signals and downstream YAP-regulated genes. We also discuss the clinical significance of the YAP signaling
network in PDAC using a recently published interactive open-access database (www.proteinatlas.org/pathology) that allows
genome-wide exploration of the impact of individual proteins on survival outcomes. Multiple YAP/TEAD-regulated genes, including
AJUBA, ANLN, AREG, ARHGAP29, AURKA, BUB1, CCND1, CDK6, CXCL5, EDN2, DKK1, FOSL1,FOXM1, HBEGF, IGFBP2, JAG1, NOTCH2,
RHAMM, RRM2, SERP1, and ZWILCH, are associated with unfavorable survival of PDAC patients. Similarly, components of AP-1 that
synergize with YAP (FOSL1), growth factors (TGFα, EPEG, and HBEGF), a specific integrin (ITGA2), heptahelical receptors (P2Y2R,
GPR87) and an inhibitor of the Hippo pathway (MUC1), all of which stimulate YAP activity, are associated with unfavorable survival
of PDAC patients. By contrast, YAP inhibitory pathways (STRAD/LKB-1/AMPK, PKA/LATS, and TSC/mTORC1) indicate a favorable
prognosis. These associations emphasize that the YAP signaling network correlates with poor survival of pancreatic cancer patients.
We conclude that the YAP pathway is a major determinant of clinical aggressiveness in PDAC patients and a target for therapeutic
and preventive strategies in this disease.
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INTRODUCTION
Pancreatic cancer, of which pancreatic ductal adenocarcinoma
(PDAC) represents the most common histological subtype, is one
of the most lethal human diseases, with overall 5-year survival
rates of 7% and a median survival period of 4–6 months1. The
incidence of this disease in the United States is estimated to
increase to 53,670 new cases in 2017. Indeed, deaths due to PDAC
are projected to increase dramatically, making the disease the
second leading cause of cancer-related deaths in the USA before
20302. Novel targets and agents for therapy and chemoprevention
are urgently needed and will most likely arise from a more
detailed understanding of the signaling mechanisms that
stimulate the promotion and progression of sub-malignant
(initiated) cells into pancreatic cancer cells and from the
identification of modifiable risk factors for PDAC. Identification
of the molecular mechanisms of PDAC promotion and drug
resistance will clearly guide the discovery of novel targets,
prognostic markers, agents for therapy and prevention and will
identify effective signature markers for use in specific and
personalized therapeutic procedures.
PDAC arises from the evolution of precursor lesions, the most
common of which are pancreatic intraepithelial neoplasias
(PanINs). Progression from these noninvasive ductal lesions to
in situ carcinomas and invasive cancers is associated with the
accumulation of genetic alterations, including activation of
mutations in the KRAS oncogene, which are widely accepted to
represent an initiating event3. Accordingly, exome sequencing has
established KRAS to be the most frequently mutated gene in PDAC
(~95%)4, 5. The majority of all missense KRAS mutations in PDAC
occur at position G12, with a G12D single amino acid substitution
being the most prevalent. These mutations prevent interactions
between KRAS-GTP and KRAS GTPase-activating proteins (GAPs),
thus leading to prolonged activation of KRAS and thereby to the
activation of downstream signaling effectors, the best character-
ized of which are the RAF/MEK/ERK and PI3K/AKT/mTOR path-
ways6, 7. Genetically engineered mouse models that recapitulate
many features of the human disease have defined a critical role for
KrasG12D in the initiation and maintenance of PDAC3, 8, 9. The
progression of pancreatic carcinogenesis requires stimulation of a
set of signaling pathways that lead to sustained cell proliferation4.
Although, a KRAS mutation is an early and necessary event in the
development of PDAC, it is not sufficient to promote the complete
carcinogenic process. Activation of other pathways by additional
mutations, including mutations in tumor suppressor genes, such
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as TP53, one of the most frequently mutated genes in human
cancer, CDKN2A, the gene encoding p16 and p14, and SMAD4
and/or environmental stimuli (obesity, type 2 diabetes mellitus)
are required for the promotion of invasive PDAC. This article
highlights a striking association between a signal transduction
network and the overall survival of patients with PDAC.
THE HIPPO/YAP/TAZ PATHWAY AND PDAC
The transcriptional co-activators yes-associated protein (YAP)10
and its paralog WW-domain-containing Transcriptional co-
Activator with a PDZ-binding motif (TAZ)11 are attracting intense
attention as fundamental points of convergence and intersection
of many signal transduction pathways that are implicated in the
regulation of development, metabolism, organ-size, positional
sensing, tissue regeneration and tumorigenesis12–14. Indeed,
multiple products of the YAP/TEAD-regulated gene network have
a major impact on these important processes, and YAP and TAZ
are increasingly recognized as potent oncogenes in many cancer
types15, especially in PDAC16–19. After a succinct overview of the
YAP/TAZ network in PDAC, the basic tenet of this article will be to
emphasize the association between the expression of each
element of the network and patient overall survival. Therefore,
this review integrates signal transduction and patient survival, and
thus differs in focus from many recent excellent reviews on the
Hippo/YAP/TAZ pathway that are available in the literature12–15, 20.
It is widely recognized that a major factor in the regulation of
YAP/TAZ activity is the Hippo pathway, which was originally
identified in Drosophila12. Canonical Hippo signals are transduced
through a serine/threonine kinase cascade, wherein Mst1/2
kinases, in complex with Sav1, phosphorylate and activate Lats1/
2 in complex with its regulatory protein MOB1/2 (Fig. 1). In
addition to Mst1/2, Hppy/MAP4Ks were identified as alternative
kinases that phosphorylate Lats1/221. In turn, Lats1/2 phosphor-
ylates YAP and TAZ, two major downstream effectors of the Hippo
pathway and novel sensors of the mevalonate and glycolytic
pathways13, 22, 23. Structurally, YAP and TAZ share nearly half of
their overall amino acid sequences, and have very similar
topologies and highly conserved residues that are located within
a consensus sequence that is phosphorylated by Lats1/2
(HXRXXS). The phosphorylation of YAP by Lats1/2 at Ser-127 and
Ser-397 (and equivalent residues in TAZ) restricts its cellular
localization to the cytoplasm and reduces the protein’s stability
(Fig. 1). When the Hippo pathway is not functional, YAP and TAZ
are dephosphorylated and translocated to the nucleus where they
bind to and activate a number of transcription factors, primarily
the TEA-domain DNA-binding transcription factors (TEAD 1–4). In
this manner, nuclear YAP and TAZ promote the expression of
multiple genes (Fig. 1). Accordingly, YAP and TAZ display a degree
of functional redundancy15, 20 but also differ in a number of ways.
For example, YAP negatively regulates TAZ, while TAZ expression
levels do not modulate YAP levels24. TAZ is more unstable than
YAP, thus these oncogenic proteins often are differentially
expressed in different cancer cell types25. Therefore, activation
of the tumor suppressor Hippo pathway in response to multiple
environmental cues, including cell/cell contacts, cell polarity and
mechanical tension, potently inhibits the transcriptional co-
activator activity of YAP and TAZ and leads to the degradation
of TAZ12, 15, 26–28.
By contrast, multitude upstream pathways positively control
YAP/TAZ transcriptional co-activator activity. These include signals
mediated by ligand-activated G protein-coupled receptors
(GPCRs), tyrosine kinase receptors, integrins and mechanical cues
(Fig. 2). A variety of signaling pathways that are activated by these
receptors, including PI3K, mTOR, PKD, and Rho/actin cytoskeleton,
feed into the YAP/TAZ pathway12, 15, 26–28. For example, a recent
study with human PDAC cells demonstrated that crosstalk
between insulin/IGF-1 receptor and GPCR systems29, 30 regulates
YAP localization, phosphorylation, and transcriptional co-activator
activity through PI3K and PKD31. Accordingly, recent studies with
other cell types demonstrated that PI3K inhibits the activity of the
Hippo pathway32, 33, thereby promoting YAP activity. Other
studies have demonstrated that PKD, a key node downstream of
GPCRs34, 35, stimulates the nuclear localization of YAP and the
activation of YAP/TEAD-regulated gene expression, most likely by
stabilizing the actin cytoskeleton28. Thus, extracellular stimuli can
Fig. 1 Hippo signaling phosphorylates YAP and regulates its nuclear/cytoplasmic distribution. When Hippo signaling is active (e.g., in
response to cell density, polarity signals, or mechanical cues) the Mst1/2 kinases, in complex with Sav1, phosphorylate and activate Lats1/2 in
complex with its regulatory protein MOB1/2. In addition to Mst1/2, MAP4Ks act as alternative kinases that phosphorylate Lats1/2. In turn,
Lats1/2 phosphorylates YAP on highly conserved residues (in red) located within a consensus sequence that is phosphorylated by Lats1/2
(HXRXXS). The phosphorylation of YAP at Ser-127 promotes its cytoplasmic retention, whereas phosphorylation at Ser-397 induces
degradation. When the Hippo pathway is off, YAP is dephosphorylated and translocated into the nucleus where YAP binds and activates the
TEAD transcription factors and stimulates the expression of multiple genes. Additional details are provided in the text
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control YAP/TAZ activity via inhibition of the Hippo pathway and/
or stabilization of the actin cytoskeleton, thereby regulating a
complex program of gene expression (Fig. 2). A recent report
indicated that in addition to YAP and TAZ, the TEAD transcription
factors also shuttle between the nucleus and the cytoplasm and
that environmental stress promotes the cytoplasmic translocation
of TEAD via p38 MAPK in a Hippo-independent manner, thus
identifying an additional level of regulation36.
The YAP/TAZ pathway assumes an added importance in PDAC
because YAP is also a key downstream target of KRAS signaling16
that is required for acinar-to-ductal metaplasia (ADM) and PanIN
progression into PDAC in genetically engineered mouse models16,
17. YAP is also a major mediator of pro-oncogenic mutant p53,
resistance to RAF/MEK inhibitors and chemotherapy in PDAC37, 38,
and TAZ supports development of pancreatic cancer39. Con-
versely, mutants that render p53 as a super suppressor of
pancreatic cancer act via inactivation of Yap40. It is of interest
that pancreas-specific deletion of Yap did not affect normal
pancreatic development and endocrine functions, but blocked the
progression of KrasG12D –induced evolution of PanINs to overt
PDAC16.
In addition to the rapid regulation of YAP activity via
phosphorylation and localization, additional pathways and epige-
netic events regulate the level of YAP/TAZ protein expression. In
this regard, the RAS pathway promotes YAP1 stability indepen-
dent of the Hippo pathway through down regulation of the
ubiquitin ligase complex substrate recognition factors SOCS5/6,
thereby increasing YAP stability41. A recent study demonstrated
that eIF5A (eukaryotic translation initiation factor 5A), which is up-
regulated by KRAS in PDAC and in KC mice (i.e., mice harboring a
Kras G12D), increases the tyrosine kinase PEAK1. In turn, the eIF5A/
PEAK1 axis enhances the expression of YAP42. It is also relevant
that YAP and mTORC1 form an amplification loop that enhances
the expression of YAP protein. Specifically, YAP stimulates
mTORC1 via down regulation of phosphatase and tensin homolog
(PTEN) and increases amino acid (leucine) transport43. In turn, the
activation of mTORC1 leads to the accumulation of YAP through
impaired autophagy44. The positive feedback loop between YAP
and mTORC1 increases YAP activity and expression.
Recent studies have demonstrated that amplification and
overexpression of YAP could substitute for mutant Kras in murine
cancers19, 45. These findings raise the important notion that YAP
not only acts downstream of Kras but also that hyper-activation
and expression of YAP can circumvent the need for Kras mutant
expression in PDAC3, 19. An important feature of PDAC is the
recruitment of immune-suppressive leukocytes, including
myeloid-derived suppressor cells and tumor-associated macro-
phages, that contribute to immune evasion3. Recently, YAP has
been shown to play a critical role in promoting an immunosup-
pressive microenvironment via the production of multiple
cytokines in PDAC46 and in other cancers47. Thus, there is
substantial evidence from preclinical studies indicating that YAP/
TAZ is at the epicenter of a signaling network that is of crucial
importance in the development of PDAC. Our next objective is to
focus on the importance of the YAP/TAZ pathway in human PDAC.
CLINICAL SIGNIFICANCE OF YAP: A PROGNOSTIC MARKER IN
PDAC
To assess the significance of the YAP pathway in human PDAC, we
will discuss the importance of YAP as a prognostic marker of
survival in patients with PDAC. A number of studies have indicated
that YAP and TAZ are overactive in tumor samples from PDAC
patients, as judged by their expression and or localization18, 19, 39.
Furthermore, a recent report identified YAP expression as an
independent prognostic marker for the overall survival of PDAC
Fig. 2 YAP is at the epicenter of a signaling network. Growth factors (TGFα, EPEG, and HBEGF) induce EGFR signaling leading to KRAS
activation, which in turn, stimulates YAP activation and increased expression. Other tyrosine kinase receptors, a specific integrin (ITGA2),
multiple GPCRs, an inhibitor of Hippo pathway (MUC1) and actin polymerization via multiple pathways also stimulate YAP activity. Activation
of YAP stimulates its coupling with TEAD, thereby promoting the expression of multiple YAP/TEAD-regulated genes that were identified in
screens in different cell types. Reference to the study or studies connecting each gene to YAP/TAZ, as well as further details concerning the
network are in the text
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patients and its association with liver metastasis48. If YAP plays a
critical role in the survival of PDAC patients, it is plausible that
upstream and downstream elements of the network, as well as
regulators of YAP activity that have been identified in a variety of
cells, are also likely to be associated with survival of patients with
PDAC, and can serve as prognostic markers. Given its important
translational implications, we explored this proposition using a
recently published interactive open-access database (www.
proteinatlas.org/pathology) to perform correlation analyses based
on mRNA expression levels of genes of the YAP pathway in PDAC
tissue and the clinical outcome (survival) of the patients49. The
data in the Pathology Atlas is based on the integration of publicly
available data from The Cancer Genome Atlas and data generated
within the framework of the Human Protein Atlas and analyzed
transcriptomics and survival in 176 PDAC patients. The results are
presented in the form of Kaplan–Meier plots and only differences
in survival with a high statistical significance (p < 0.001) are taken
into consideration. We also performed additional searches of the
literature for studies using different patient cohorts that validate
the conclusions drawn from the Pathology Atlas.
As expected, increased expression of YAP is associated
significantly with an unfavorable prognosis (survival) in PDAC
patients who were included in the Pathology Atlas49. Antibody
staining, which is also included in the Pathology Atlas, is
consistent with the mRNA expression data and is in agreement
with other studies39, 48, localizes YAP/TAZ to the cancer cells.
As illustrated in the Kaplan–Meier plot in Fig. 3, none of the
patients of the population with higher levels of YAP mRNA
expression (n = 36) survived for 5 years, although 32% of the
population (n = 140) with lower levels of YAP mRNA survived for
5 years or more. In agreement with a recent report using a
different cohort of patients48, an increase in the expression of
YAP is an unfavorable prognostic marker for survival in patients
with PDAC.
MOLECULES DOWNSTREAM AND UPSTREAM OF YAP ARE
UNFAVORABLE PROGNOSTIC MARKERS IN PDAC
As indicated in previous sections, YAP and TAZ constitute points
of convergence of multiple upstream pathways and in turn,
regulate the expression of multiple genes. In most cases, the
regulation of gene expression by YAP/TAZ/TEAD occurs via distal
enhancer elements50. We performed a correlation analysis
between mRNA expression of genes that are downstream targets
of YAP/TAZ in a variety of cell types and survival of PDAC patients
by mining the data that are available in the recently available
Pathology Atlas49. As highlighted in Fig. 4, multiple YAP/TEAD-
regulated genes are significantly associated (p < 0.001) with
unfavorable prognosis in PDAC49. These include AJUBA50, ANLN51,
ANXA350, AREG28, ARHGAP1952, ARHGAP2953, AURKA19, BUB119, 50,
CCNA250, CCND150, 54, CDK650, 55, CEP5550, CXCL531, 47, 50,
DKK150, 56, EDN250, 57, EZR50, 58, FOXM159, HBEGF50, IGFBP260,
JAG150, 61, KIF2C50, KIF18B50, KIF2350, MSLN50, 62, NOTCH263,
PRMT550, RRM250, SERP150, RHAMM23, and ZWILCH50. Each refer-
ence identifies the study or studies that connected the expression
of the corresponding gene to YAP/TAZ/TEAD activity. In addition,
independent studies using different patient populations demon-
strated that the expression of YAP/TAZ/TEAD-regulated genes,
including ANLN64, AREG65, CCND166, DKK167, EZR58, FOSL168,
FOXM169, MSLN70, RHAMM71, RRM272, and SERP173, is associated
with shorter survival in patients with PDAC.
It is important to emphasize that the protein products of YAP/
TEAD-regulated genes that are associated with PDAC survival
regulate a set of fundamental biological processes in cancer
development. For example, AREG, HBEGF, CCND1, and
RRM2 stimulate cell proliferation; AURKA, BUB1, CEP55, KIF23,
and ZWILCH participate in mitosis;68, 74 YAP cooperates with
FOXM1 to promote chromosome instability59, and CXCL5 med-
iates communication between cancer cells and myeloid-derived
suppressor cells47, which contributes to the immunosuppressive
microenvironment characteristic of PDAC. Other YAP/TEAD-
regulated gene products are involved in the regulation of
developmental pathways, including NOTCH, DKK1/WNT, and the
Hippo pathway itself via AJUBA75. AURKA also inhibits LKB1/AMPK
signaling thereby leading to YAP activation (see below). Further-
more, proteins that are encoded by the YAP-regulated genes EZR
and IGFBP2 (ezrin and IGFBP2, respectively) promote metastasis
and epithelial-to-mesenchymal transition (EMT) in pancreatic
cancer cells76. In turn, EMT contributes to the loss of cell polarity
and thus to inhibition of the Hippo pathway, thereby reinforcing
YAP activation. It is also of interest that the expression of some
YAP/TEAD-regulated genes, including CTGF (encoding for con-
nective tissue growth factor) have not been identified as
prognostic markers of PDAC, but are likely to play a role in
pancreatic carcinogenesis77.
In addition to AREG (amphiregulin) and HBEGF (heparin-binding
EGF), which stimulate YAP/TEAD signaling via autocrine/paracrine
stimulation of EGFR78 as part of positive feedback loops, other
EGFR ligands, including TGFα and epiregulin (EPEG) that stimulate
YAP activity are also associated with shorter overall survival in
PDAC (Fig. 4). Similarly, the increased expression of MET79, ITGA280,
IQGAP181, EZR82, MUC183, PRKC84, and YES185 which enhance YAP
co-transcriptional activity through different mechanisms, is
associated with shorter survival in patients with PDAC (Fig. 4).
Interestingly, the activator protein-1 (AP-1, dimer of JUN and FOS
proteins) factors have been shown to potentiate YAP/TAZ/TEAD-
dependent gene expression via enhancers rather than
promoters50. In line with the notion that YAP/TAZ is at the center
of a signaling network that is associated with patient survival, the
expression of FOSL1, a component of AP-1, is also strongly
associated (p < 0.001) with an unfavorable prognosis in PDAC, as
has also been shown recently in an independent report68.
GPCR signaling is one of the major upstream signals that
regulate YAP/TAZ activation in a variety of systems, including
PDAC31. In this context, the expression of genes encoding the
lysophosphatidic acid (LPA) receptor GPR8786, the purinergic GPCR
P2Y2R
87 and the GPCR agonist EDN2 (endothelin 2)57, a down-
stream target of YAP, are also associated with an unfavorable
prognosis in PDAC. A recent independent study confirmed that
overexpression of GPR87 is correlated with a poor prognosis in
PDAC88. By contrast, the expression of GRK6, which phosphor-
ylates GPCRs thus opposing their signaling output89, is associated
with a favorable survival prognosis in PDAC (Fig. 4).
As mentioned above, the organization of the actin cytoskeleton
is a master regulator of YAP/TAZ nuclear localization and
activity90, 91. Interestingly, a number of proteins that are encoded
Fig. 3 Kaplan–Meier plots for YAP expression in PDAC. The image
was reproduced from the Human Protein Atlas (version 17) available
at www.proteinatlas.org. The link is: http://www.proteinatlas.org/
ENSG00000137693YAP1/pathology/tissue/pancreatic±cancer.
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Fig. 4 YAP signaling is associated with unfavorable prognosis for PDAC. Multiple YAP/TEAD-regulated genes are associated with unfavorable
survival of PDAC patients (indicated in red). Growth factors (TGFα, EPEG, and HBEGF), a specific integrin (ITGA2), GPCRs (P2Y2R, GPR87) or an
inhibitor of the Hippo pathway (MUC1) that stimulate YAP activity are also associated with unfavorable survival in PDAC. Conversely, YAP
inhibitory pathways, including STRAD/LKB-1, PKA/LATS, and TSC/mTORC1 are associated with a favorable prognosis (indicated in blue). The
key feature is that each component of the network has an impact on survival of PDAC patients, as derived from the Pathology Atlas49, as well
as additional references cited in the text. An unfavorable prognosis for PDAC is in red and a favorable prognosis for PDAC is in blue. All
prognostic associations are highly statistically significant (p< 0.001). Further details are in the text
Fig. 5 Kaplan–Meier plots for gene expression of the YAP signaling network in PDAC. Images were reproduced from the Human Protein Atlas
(version 17) available at www.proteinatlas.org. The links to the specific genes shown are as follows: AHNAK, http://www.proteinatlas.org/
ENSG00000124942AHNAK/pathology/tissue/pancreatic±cancer, ANLN, http://www.proteinatlas.org/ENSG00000011426ANLN/pathology/
tissue/pancreatic±cancer CDK6, http://www.proteinatlas.org/ENSG00000105810-CDK6/pathology/tissue/pancreatic±cancer EPS8, http://
www.proteinatlas.org/ENSG00000151491-EPS8/pathology/tissue/pancreatic±cancer JAG1, http://www.proteinatlas.org/ENSG00000101384-
JAG1/pathology/tissue/pancreatic±cancer PKA, http://www.proteinatlas.org/ENSG00000072062-PRKACA/pathology/tissue/pancreatic±cancer
YAP signaling web correlates with PDAC survival
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by YAP/TEAD-regulated genes also influence the organization of
the actin cytoskeleton, suggesting the existence of feedbacks
loops. The epidermal growth factor receptor pathway substrate 8
(Eps8), a regulator of actin remodeling that is up-regulated in
>70% of PDACs and induces YAP translocation to the nucleus and
transcriptional activation92, is associated with an unfavorable
prognosis in PDAC49. ANLN and AHNAK, proteins that are
implicated in actin cytoskeleton organization93 and thus, poten-
tially in YAP regulation, are also associated with unfavorable
survival in PDAC. Indeed, AHNAK, ANLN, CDK6, EPS8, and JAG1 are
among the genes with the highest significance associated
with unfavorable prognoses in PDAC (Kaplan–Meier plots in Fig. 5;
p < 4.1e−6) and are all either upstream or downstream of
YAP/TEAD (Fig. 4).
PATHWAYS THAT OPPOSE YAP SIGNALING ARE FAVORABLE
PROGNOSTIC MARKERS IN PDAC
In recent years, it has become apparent that, in addition to the
cascade of Hippo kinases, other important pathways also inhibit
YAP/TAZ functions. AMP–activated protein kinase (AMPK) is a well-
known sensor of cellular energy that is activated when ATP
concentrations decrease and 5′-AMP concentrations increase94.
AMPK opposes YAP activity at different levels, including direct
phosphorylation of YAP at Ser-94, a key residue for the interaction
between YAP and TEAD35, 95. The tumor suppressor LKB-1/STK11 is
the major kinase for phosphorylating the AMPK activation loop at
Thr-17296. Interestingly, STE20-related adaptor (STRAD), a co-factor
that allosterically stimulates LKB-1 activity and thus promotes
AMPK activity, is a favorable prognostic marker in pancreatic
cancer (Fig. 4). Furthermore, the protein kinases of the MARK
family (e.g., MARK1) that also function downstream of LKB-1 and
repress YAP activity97 are also associated with a favorable
prognosis in pancreatic cancer.
A number of other studies have indicated that the cAMP/PKA
pathway also inhibits YAP activity98, at least in part via stimulation
of LATS kinases99. Accordingly, expression of PKA is associated
with a favorable prognosis in PDAC, presumably via inhibition of
YAP function (Fig. 4).
As mentioned above, mTORC1 is part of an amplification loop
that leads to YAP expression and enhanced activity. The
heterodimer of the tumor suppressors TSC2 (tuberous sclerosis
2, also known as tuberin) and TSC1 (tuberous sclerosis 1, also
known as hamartin) opposes mTORC1 signaling100, 101 by acting
as a GTPase-activator protein for the small G protein Rheb,
a potent activator of mTORC1 signaling in its GTP-bound
state102, 103. Importantly, increased expression of TSC2 and TSC1
is associated with a favorable prognosis for patients with PDAC
(Fig. 4).
TARGETING THE YAP SIGNAL TRANSDUCTION PATHWAY
As a result of the developments discussed in this article, there is
intense interest in targeting YAP/TAZ in PDAC therapy and
chemoprevention. Although inhibition of the activity of transcrip-
tion factors or their co-activators is a challenging strategy, recent
preclinical and epidemiological evidence suggest new approaches
for targeting the YAP/TAZ signal transduction pathway.
Many studies have shown that the mevalonate pathway is
markedly up-regulated in several epithelial cancers via mutant
p5395, 104, 105 and Akt/mTORC195. Statins are specific inhibitors of
3-hydroxy-methylglutaryl (HMG) CoA reductase106 which is the
rate-limiting enzyme in the generation of mevalonate, the first
step in the biosynthesis of isoprenoids leading to farnesyl
pyrophosphate (FPP), geranylgeranyl pyrophosphate (GG-PP)
and cholesterol. Transfer of the geranylgeranyl moiety to a
COOH-terminal cysteine of Rho GTPases is critical for their
function in signal transduction. In turn, active Rho (i.e., Rho-GTP)
is essential for YAP/TAZ activation via actin cytoskeletal organiza-
tion. Statins, which are usually well tolerated and generally safe,
are used to treat hypercholesterolemia and prevent cardiovascular
diseases. Although initially inconsistent, mounting epidemiologi-
cal studies indicate that the use of statins is associated with
a reduced risk and beneficial effects in PDAC107–111, especially
in men110, 111. For example, a recent large study demonstrated
that statin use was associated with a 34% reduced risk of PDAC,
with a stronger association in male subjects110. In addition to their
potential use in primary prevention, statins have also been shown
to improve the survival of patients after resection of primary PDAC
tumors, indicating a possible role of statins in the prevention of
secondary PDAC107, 108, 112. Of great interest, a high-throughput
screen of compounds capable of altering the subcellular localiza-
tion of YAP led to the identification of statins as potential YAP
inhibitors via the inhibition of Rho113. An independent study that
examined the regulation of the expression of the receptor for
hyaluronan-mediated motility (RHAMM) also led to the discovery
that statins inhibit YAP/TAZ activity23. Consequently, statins
provide a plausible strategy for targeting YAP/TAZ function and
thus, an explanation for the mechanism by which these drugs
appear to exert beneficial effects in PDAC. In view of these
considerations, prospective clinical trials targeting YAP/TAZ with
statins in primary or secondary PDAC chemoprevention are
needed.
Metformin (1,1-dimethylbiguanide hydrochloride) is the most
widely prescribed drug for the treatment of type 2 diabetes
mellitus (T2DM) worldwide94, 114. Epidemiological studies suggest
that administration of metformin may reduce cancer incidence
and mortality in diabetic patients115. A recent meta-analysis
indicated that metformin improved survival in PDAC patients with
resection and patients with locally advanced tumors, but not in
patients with metastatic PDAC116. In mechanistic studies, we
demonstrated that metformin potently stimulated AMPK activa-
tion in intact human PDAC cells that were cultured with
physiological concentrations of glucose in the medium117, 118,
and inhibited mTORC1, ERK and mitogenic signaling via AMPK at
low concentrations117–119. Metformin also inhibited the growth of
PDAC xenografts29, 120 and the development of PanINs and PDAC
in KC mice121. As indicated above, AMPK, a well-known sensor of
cellular energy94, opposes YAP function via direct phosphorylation
of YAP at Ser-94122, 123 as well as by phosphorylation of HMG-CoA
reductase at Ser-872, which inhibits mevalonic acid synthesis124.
These studies imply a connection between cellular energy status,
lipid metabolism, AMPK and YAP/TAZ function. Because statins
and metformin interfere with YAP function through different
mechanisms, it is plausible that a combination of these agents
additively or synergistically may suppress YAP/TAZ activity and
thereby exerts cancer-preventive activity at low concentrations of
each agent.
As indicated in Fig. 4, YAP/TAZ leads to an increase of the Notch
pathway, which is likely to contribute to the oncogenic effects of
YAP/TAZ. Indeed, pharmacological inhibitors of Notch activation
reduced PDAC xenograft growth in preclinical models125 but were
not effective in PDAC patients with advanced disease126.
Upstream of YAP, inhibitors of EGFR have already shown a small
favorable effect in PDAC127, however, other pathways can bypass
EGFR. mTORC1 is part of an amplification loop that leads to YAP
expression and enhanced activity, and the heterodimer of TSC2
and TSC1 which opposes mTORC1 signaling100, 101, is associated
with a favorable prognosis for patients with PDAC. A number of
mTOR inhibitors are available but their efficacy decreases with
time and YAP provides one route for escape128. There is a clear
need for further studies using combinations of drugs that target
the YAP network at different levels to determine their possible
anticancer activity.
A number of small molecule tyrosine kinase inhibitors, including
dasatinib and pazopanib, induce YAP/TAZ phosphorylation and
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cytoplasmic degradation and reduce their nuclear translocation,
suggesting another approach for restraining YAP/TAZ activity129.
Although these inhibitors frequently induce drug resistance via
enhancement of compensatory pathways130 these tyrosine
kinase inhibitors could be considered as part of a combinatorial
strategy.
A number of laboratories have searched for compounds that
inhibit the nuclear localization of YAP and/or the interaction of
YAP with TEAD131. Verteporfin (trade name Visudyne), a member
of the porphyrin family, is used in photodynamic therapy of
ophthalmological diseases to destroy new abnormal vessels with
few side effects. Verteporfin, without light activation, has been
reported to inhibit YAP/TEAD complex formation, thereby acting
as a suppressor of cell growth132–134. However, in addition to its
putative inhibitory effect on YAP/TEAD function, verteporfin also
induces protein cross-linking via a non-enzymatic mechanism135,
136. Thus, verteporfin provides a plausible strategy for interfering
with YAP/TEAD function within cells, but it has additional cellular
effects and therefore its specificity as a YAP/TEAD antagonist has
been questioned.
Mammalian Vestigial-like 4 (VGLL4) is a tumor suppressor that
does not bind directly to DNA but competes with YAP for binding
TEADs137, 138. A peptide capable of mimicking the function of
VGLL4 suppressed tumor growth in vitro and in vivo, implying that
disrupting the YAP-TEAD interaction by a VGLL4-mimicking
peptide may be a therapeutic strategy for inhibiting YAP-
mediated cell proliferation137. However, this approach has
limitations, including the permeability of the peptide across the
plasma membrane and its stability. Importantly, crystal structures
of YAP/TEAD139 and TAZ/TEAD140 complexes have been solved,
opening new avenues for computational modeling of compounds
that disrupt these molecular complexes within intact cells141, 142.
CONCLUSION AND IMPLICATIONS
PDAC is generally a fatal disease with no efficacious treatment
modalities. It is important that strategies to prevent the disease be
explored, especially since its incidence is projected to increase
markedly in the next decade. YAP and TAZ, the major downstream
targets of the Hippo tumor suppressor pathway (Fig. 1), are also
regulated by a multitude of other inputs, including KRAS (Fig. 2).
The data discussed in this article indicate that not only YAP (Fig. 3)
but also many components of the YAP network are associated
with overall survival in PDAC (Fig. 4). Indeed, multiple downstream
targets of YAP/TAZ/TEAD are associated with unfavorable survival
of PDAC patients. Similarly, multiple components that stimulate
YAP activity, including AP-1 which synergizes with YAP (FOSL1)
and growth factors (TGFα, EPEG, and HBEGF), GPCRs (P2Y2R,
GPR87), a specific integrin (ITGA2) or an inhibitor of the Hippo
pathway (MUC1), are all convincingly associated with unfavorable
survival in PDAC (Fig. 4). In sharp contrast, increased expression of
YAP inhibitory pathways (LKB-1, PKA, TSC) portends a favorable
prognosis. All of these associations which have been derived from
the recently published interactive open-access database (www.
proteinatlas.org/pathology) that allows genome-wide exploration
of the impact of individual proteins on survival outcomes,
emphasize that increased expression of the YAP signaling web
correlates with poorer survival of patients with PDAC. This analysis
convincingly supports the notion that the YAP network is a target
for therapeutic and preventive strategies in PDAC. The association
of patient survival to the YAP/TAZ signaling network strongly
suggests a need for novel combinatorial strategies for targeting
the YAP network in PDAC, one of the most lethal diseases.
Upstream of YAP, EGFR inhibitors have already shown a small
favorable effect in PDAC127, however, other pathways, including
other tyrosine kinase receptors, can bypass EGFR and thus
stimulate YAP leading to drug resistance. As indicated above,
statins and metformin interfere with YAP function through
different mechanisms, and recent epidemiological studies indicate
that their administration is associated with beneficial effects in
PDAC143, 144. Downstream of YAP, inhibitors of NOTCH pathway
activation have shown activity in preclinical models, but were not
pursued further because they did not exert any response in
advanced PDAC patients. Thus, there are drugs, some of which are
FDA-approved and in clinical use, that target the YAP network at
different levels, thus providing a rationale for designing combi-
natorial strategies in both preclinical settings and in future clinical
trials for PDAC. Furthermore, there are major efforts to develop
potent compounds that disrupt YAP/TEAD and TAZ/TEAD
molecular complexes within intact cancer cells.
Given the strong correlation of the YAP signaling network with
patient survival that is demonstrated in this article, it is
conceivable that a combination of these drugs will suppress
YAP/TAZ activity synergistically and thereby exert cancer-
preventive activity at low concentrations of each agent, a
proposition that warrants further experimental, preclinical and
clinical work.
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